(Q52612765)
Statements
Clinical, pharmacodynamic, and pharmacokinetic evaluation of BNC105P: a phase I trial of a novel vascular disrupting agent and inhibitor of cancer cell proliferation (English)
Danny Rischin
David C Bibby
Geoff Chong
Gabriel Kremmidiotis
Annabell F Leske
Clayton A Matthews
Shirley S Wong